BioCardia reports Q3 2026 results, cites progress on Japan filing and Helix FDA pathway
The company said it completed PMDA pre-filing requirements in Japan for CardiAMP and expects to submit a Helix De Novo application to FDA in early 2027.
BioCardia, Inc. reported third quarter 2026 results on November 12, 2026, alongside its Form 10-Q for the period ended September 30, 2026.
On its lead cardiac cell therapy program, the company said it had successfully completed the process with Japan's Pharmaceuticals and Medical Devices Agency concerning the application materials required for regulatory approval, and that questions remaining before submission had been addressed to PMDA's satisfaction.1 BioCardia said it is preparing clinical data sets for submission to PMDA and the FDA, working with partners on an electronic trial master file and good clinical practice audits, and has engaged a Designated Marketing Authorization Holder as its local regulatory representative in Japan.1 Separately, the company said it continues to actively enroll in the CardiAMP HF II trial, with four clinical sites enrolled and actively recruiting patients and seven additional sites being onboarded.1
On the Helix transendocardial delivery catheter, BioCardia said FDA accepted its Q2 Pre-Submission meeting minutes without changes in August, and the company submitted a revised Pre-Submission in September, which FDA accepted in October.1 FDA aims to issue written feedback or hold a meeting within 70 calendar days, and the company said it expects to hear back within the next six weeks.1 BioCardia said it expects to complete the De Novo submission in the first quarter of 2027, with approval targeted for mid-2027 if FDA meets its 150-day review goal under MDUFA guidelines.1
The company listed anticipated milestones including a CardiAMP Cell Therapy Shonin submission to Japan's PMDA in Q4 2026/Q1 2027, a CardiAMP HF trial peer-reviewed manuscript in Q1 2027, and a Heart3D FDA submission in Q1 2027.1
On financials, BioCardia said it ended the quarter with cash and cash equivalents totaling $2.2 million, providing anticipated runway into 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.